Yeast display of proteins in the periplasmic space
US-2024102202-A1 · Mar 28, 2024 · US
US10106787B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10106787-B2 |
| Application number | US-201514708073-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 8, 2015 |
| Priority date | May 12, 2014 |
| Publication date | Oct 23, 2018 |
| Grant date | Oct 23, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed to methods for systematic identification of cellular ligands, disease-associated ligands, age-related ligands and receptor-specific ligands. Disease-associated ligands are promising targets to develop novel ligand-based therapies. The methods are broadly applicable to any type of cells or diseases in in vitro and in vivo settings. This invention further used the methods to identify Scg3 as a disease-related angiogenic factor for the therapy of diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, vascular age-related macular degeneration, diabetic foot and cancers.
Opening claim text (preview).
What is claimed is: 1. A high throughput ligand screening method of ligandomics to globally identify cell-wide endogenous binding ligands for systematic identification of disease-associated, age-related or receptor-specific ligands, comprising the steps of: (a) phage display with open reading frame phage display (OPD) cDNA libraries to enrich phage clones displaying endogenous cellular ligands with binding activity to cell surface; (b) global identification of all enriched cell-binding endogenous ligands to map entire ligandome profiles by next generation DNA sequencing (NGS) to identify the coding cDNA sequences of all enriched cell-binding ligands; (c) binding activity quantification of all identified cell-wide endogenous ligands for entire ligandome profiles by NGS to quantify the cDNA copy numbers of all enriched ligands as their relative binding activities; (d) global binding activity comparison of entire ligandome profiles to systematically identify disease-associated, age-related or receptor-specific endogenous ligands. 2. The method of claim 1 , wherein the ligandomics comprises open reading frame phage display (OPD) cDNA libraries of cellular proteins for high efficient identification of all endogenous cell-binding ligands. 3. The method of claim 1 , wherein said the ligandomics is performed with a specific type of cells or a group of cells to enrich phage clones displaying endogenous cell-binding ligands, comprising diseased cells, healthy cells, aged cells, young cells, receptor-expressing cells or receptor-deficient or silenced cells. 4. The method of claim 1 , wherein the ligandomics comprises cell-based binding selection to enrich cell-binding phage clones displaying endogenous cellular ligands, and wherein the binding selection procedure comprises the binding of OPD cDNA libraries to cell surface, washing, and recovery of bound phage clones displaying endogenous ligands. 5. The method of claim 1 , wherein ligandomics comprises global identification of all enriched cell-binding endogenous ligands by NGS with simultaneous binding activity quantification, and wherein quantitative binding activity comparison of entire ligandome profiles for diseased versus healthy cells to systematically identify disease-associated ligands, for aged versus young cells to systematically identify age-related ligands and for receptor-expressing versus receptor-deficient or silenced cells to systematically identify receptor-specific ligands. 6. The method of claim 1 , wherein the ligandomics comprises T7 phage display vector displaying OPD cDNA libraries to enrich and identify entire cell-binding endogenous ligands, and wherein cell-binding ligands exclude phagocytosis ligands.
Angiogenesic factors; Angiogenin · CPC title
against growth factors {; against growth regulators} · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title
Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.